CD27 and myasthenia gravis: In contrast, rituximab treated MuSK-MG subjects showed significantly reduced CD27 expression in CD11c+ B cells when compared to untreated MuSK-MG subjects (Figure 5G), likely reflecting the increased frequency of naïve cells in the CD11c+ B cell population (Figure 2C).